HUP0000941A2 - Szulfonamidszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents
Szulfonamidszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásukInfo
- Publication number
- HUP0000941A2 HUP0000941A2 HU0000941A HUP0000941A HUP0000941A2 HU P0000941 A2 HUP0000941 A2 HU P0000941A2 HU 0000941 A HU0000941 A HU 0000941A HU P0000941 A HUP0000941 A HU P0000941A HU P0000941 A2 HUP0000941 A2 HU P0000941A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aralkyl
- attached
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- -1 aralkenyl Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004476 heterocycloamino group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
Abstract
A találmány szerinti (I) általános képletű vegyületek - a képletben R1 és R2 jelentése egymástól függetlenül hidrogénatom, alkil-,alkenil-, halogén-alkil-, cikloalkil-, cikloalkil-alkil-, aril-,aralkil-, heteroaril-, heteroaralkil-, heterociklikus,heterocikloalkil-, heteroalkil- vagy -(alkilén)-C(O)-X csoport; vagy R1 és R2 a szénatommal együtt, amelyhez kapcsolódik, karbociklikusvagy heterociklikus csoportot képez; R3 jelentése hidrogénatom, alkil-, alkenil-, halogén-alkil-,cikloalkil-, cikloalkil-alkil-, aril-, aralkil-, aralkenil-,heteroaril-, heteroaralkil-, heteroaralkenil-, heterocikloalkil-,heteroalkil-, (difenil-metil)-alkil- vagy -(alkilén)-C(O)-X csoport;vagy R3 R1-gyel vagy R2-vel és azokkal az atomokkal együtt, amelyekhezkapcsolódnak, heterocikloaminocsoportot képeznek; R10 jelentése -NR11OR12 csoport, ahol R11 és R12 jelentése egymástól függetlenül hidrogénatom, alkil- vagyaralkilcsoport; R20 és R21 jelentése egymástól függetlenül hidrogénatom, alkil-,heteroalkil-, cikloalkil-, cikloalkil-alkil-, aril-, aralkil-,aralkenil-, heteroaralkil- vagy heteroaralkenilcsoport; vagy R20 és R21a nitrogénatommal együtt, amelyhez kapcsolódik,heterocikloaminocsoportot vagy adott esetben helyettesítetttetrahidropiridingyűrűt vagy hexahidroazepingyűrűt képez; vagy R20vagy R21 R3-mal együtt alkiléncsoportot képez - és gyógyászatilagalkalmas sóik, előgyógyszereik (prodrug), egyes izomerjeik és azizomerek keverékei; azzal a feltétellel, hogy R20 és R21 anitrogénatomma legyütt, amelyhez kapcsolódik, nem képezmorfolinogyűrűt abban az esetben, (i) ha R1 és R3 hidrogénatomot és R2 aralkilcsoportot képvisel; vagy (ii) ha R1 és R3 az atomokkal együtt, amelyekhez kapcsolódnak,tetrahidroizokinolingyűrűt képeznek, és R2 jelentése hidrogénatom -metalloproteáz inhibitorok, így alkalmasak például rheumatoidarthritis, osteoarthritis, sclerosis multiplex, osteoporosis, krónikustüdőelzáródásos betegség, aberráns angiogenezis, tumormetasztázis,szaruhártya-fekélyesedés kezelésére. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3671497P | 1997-01-23 | 1997-01-23 | |
US6220997P | 1997-10-16 | 1997-10-16 | |
PCT/EP1998/000180 WO1998032748A1 (en) | 1997-01-23 | 1998-01-14 | Sulfamide-metalloprotease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0000941A2 true HUP0000941A2 (hu) | 2001-04-28 |
HUP0000941A3 HUP0000941A3 (en) | 2002-06-28 |
Family
ID=26713422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000941A HUP0000941A3 (en) | 1997-01-23 | 1998-01-14 | Sulfamide derivatives, process for producing them, pharmaceutical compositions containing them and their use |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP0958287B2 (hu) |
JP (1) | JP3563411B2 (hu) |
KR (1) | KR100377696B1 (hu) |
CN (1) | CN1093125C (hu) |
AR (1) | AR011425A1 (hu) |
AT (1) | ATE223909T1 (hu) |
AU (1) | AU730127B2 (hu) |
BG (1) | BG103586A (hu) |
BR (1) | BR9807508A (hu) |
CA (1) | CA2278694C (hu) |
DE (2) | DE69807845T2 (hu) |
DK (1) | DK0958287T3 (hu) |
EA (1) | EA002810B1 (hu) |
ES (2) | ES2183331T3 (hu) |
FR (1) | FR2758559A1 (hu) |
GB (1) | GB2321641B (hu) |
HR (1) | HRP980036A2 (hu) |
HU (1) | HUP0000941A3 (hu) |
ID (1) | ID22849A (hu) |
IL (1) | IL130802A0 (hu) |
IS (1) | IS5125A (hu) |
IT (1) | IT1298163B1 (hu) |
MA (1) | MA26467A1 (hu) |
NO (1) | NO313635B1 (hu) |
NZ (1) | NZ336625A (hu) |
OA (1) | OA11078A (hu) |
PA (1) | PA8445301A1 (hu) |
PE (1) | PE57399A1 (hu) |
PL (1) | PL334846A1 (hu) |
PT (1) | PT958287E (hu) |
TN (1) | TNSN98012A1 (hu) |
TR (1) | TR199901765T2 (hu) |
UY (1) | UY24854A1 (hu) |
WO (1) | WO1998032748A1 (hu) |
YU (1) | YU34599A (hu) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
HN2000000052A (es) * | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
CA2374460A1 (en) * | 1999-06-04 | 2000-12-14 | Astrazeneca Ab | Inhibitors of metalloproteinases |
US6677355B1 (en) * | 1999-08-18 | 2004-01-13 | Warner-Lambert Company | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
CA2396965C (en) * | 2000-02-21 | 2010-03-16 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
AU2001232113A1 (en) * | 2000-02-21 | 2001-09-03 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
US6495358B1 (en) * | 2000-04-19 | 2002-12-17 | Wichita State University | Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes |
US6897237B2 (en) | 2000-04-28 | 2005-05-24 | Shionogi & Co. Ltd. | MMP-12 inhibitors |
US6492171B2 (en) | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
JP4219810B2 (ja) * | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Mmp阻害作用を有するスルホンアミド誘導体 |
JP4606027B2 (ja) * | 2002-04-03 | 2011-01-05 | トポターゲット ユーケー リミテッド | Hdac阻害剤としてのピペラジン結合を有するカルバミン酸化合物 |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EP1511488B1 (en) * | 2002-06-12 | 2013-05-22 | Symphony Evolution, Inc. | Human adam-10 inhibitors |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
DE10344936A1 (de) * | 2003-09-27 | 2005-04-21 | Aventis Pharma Gmbh | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
CN1997370B (zh) * | 2004-05-19 | 2011-06-01 | 索尔瓦药物有限公司 | N-氨磺酰-n'-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途 |
US7777036B2 (en) * | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
DE102004060229A1 (de) | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
WO2007102392A1 (ja) | 2006-03-03 | 2007-09-13 | Shionogi & Co., Ltd. | Mmp-13選択的阻害剤 |
JPWO2008053913A1 (ja) | 2006-11-02 | 2010-02-25 | 塩野義製薬株式会社 | Mmp−13を選択的に阻害するスルホニルウレア誘導体 |
WO2008147764A1 (en) * | 2007-05-23 | 2008-12-04 | Array Biopharma, Inc. | Mmp inhibitors and methods of use thereof |
AR068849A1 (es) | 2007-10-12 | 2009-12-09 | Basf Se | Procedimiento para la preparacion de diamidas de acido sulfonico |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
WO2011011186A2 (en) * | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
EP2718279B1 (en) * | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
PL3297992T3 (pl) | 2015-05-22 | 2020-07-27 | Chong Kun Dang Pharmaceutical Corp. | Heterocykloalkilowe związki pochodne jako selektywne inhibitory deacetylazy histonowej oraz zawierające je kompozycje farmaceutyczne |
CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH617318A5 (en) † | 1975-09-30 | 1980-05-30 | Ciba Geigy Ag | Microbicidal composition. |
US5140009A (en) * | 1988-02-10 | 1992-08-18 | Tap Pharmaceuticals, Inc. | Octapeptide LHRH antagonists |
US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
IE68045B1 (en) * | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
WO1993006127A1 (en) * | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
GB9211707D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH10504522A (ja) † | 1994-05-04 | 1998-05-06 | ノバルティス アクチエンゲゼルシャフト | 殺微生物剤としてのn−スルホニルおよびn−スルフィニルアミノ酸アミド |
DE19507447A1 (de) † | 1995-03-03 | 1996-09-05 | Vitronic Dr Ing Stein Bildvera | Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC |
BR9611479B1 (pt) * | 1995-11-13 | 2009-01-13 | Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. | |
ATE225343T1 (de) * | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
1998
- 1998-01-14 AU AU66140/98A patent/AU730127B2/en not_active Ceased
- 1998-01-14 PT PT98907943T patent/PT958287E/pt unknown
- 1998-01-14 TR TR1999/01765T patent/TR199901765T2/xx unknown
- 1998-01-14 CN CN98803233A patent/CN1093125C/zh not_active Expired - Fee Related
- 1998-01-14 DE DE69807845T patent/DE69807845T2/de not_active Expired - Lifetime
- 1998-01-14 BR BR9807508A patent/BR9807508A/pt not_active Application Discontinuation
- 1998-01-14 IL IL13080298A patent/IL130802A0/xx unknown
- 1998-01-14 EA EA199900643A patent/EA002810B1/ru not_active IP Right Cessation
- 1998-01-14 KR KR10-1999-7006632A patent/KR100377696B1/ko not_active IP Right Cessation
- 1998-01-14 HU HU0000941A patent/HUP0000941A3/hu unknown
- 1998-01-14 WO PCT/EP1998/000180 patent/WO1998032748A1/en not_active Application Discontinuation
- 1998-01-14 CA CA002278694A patent/CA2278694C/en not_active Expired - Fee Related
- 1998-01-14 EP EP98907943A patent/EP0958287B2/en not_active Expired - Lifetime
- 1998-01-14 NZ NZ336625A patent/NZ336625A/en unknown
- 1998-01-14 YU YU34599A patent/YU34599A/sh unknown
- 1998-01-14 JP JP53153798A patent/JP3563411B2/ja not_active Expired - Fee Related
- 1998-01-14 AT AT98907943T patent/ATE223909T1/de not_active IP Right Cessation
- 1998-01-14 ID IDW990716A patent/ID22849A/id unknown
- 1998-01-14 PL PL98334846A patent/PL334846A1/xx unknown
- 1998-01-14 ES ES98907943T patent/ES2183331T3/es not_active Expired - Lifetime
- 1998-01-14 DK DK98907943T patent/DK0958287T3/da active
- 1998-01-20 AR ARP980100227A patent/AR011425A1/es active IP Right Grant
- 1998-01-20 PE PE1998000043A patent/PE57399A1/es not_active Application Discontinuation
- 1998-01-20 IT IT98MI000091A patent/IT1298163B1/it active IP Right Grant
- 1998-01-21 MA MA24932A patent/MA26467A1/fr unknown
- 1998-01-21 FR FR9800601A patent/FR2758559A1/fr not_active Withdrawn
- 1998-01-21 PA PA19988445301A patent/PA8445301A1/es unknown
- 1998-01-22 GB GB9801393A patent/GB2321641B/en not_active Expired - Fee Related
- 1998-01-22 UY UY24854A patent/UY24854A1/es not_active IP Right Cessation
- 1998-01-22 DE DE19802350A patent/DE19802350A1/de not_active Withdrawn
- 1998-01-22 ES ES009800113A patent/ES2136037B1/es not_active Expired - Fee Related
- 1998-01-22 TN TNTNSN98012A patent/TNSN98012A1/fr unknown
- 1998-01-23 HR HR60/062,209A patent/HRP980036A2/hr not_active Application Discontinuation
-
1999
- 1999-07-19 BG BG103586A patent/BG103586A/bg unknown
- 1999-07-22 NO NO19993587A patent/NO313635B1/no not_active IP Right Cessation
- 1999-07-22 IS IS5125A patent/IS5125A/is unknown
- 1999-07-23 OA OA9900162A patent/OA11078A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0000941A2 (hu) | Szulfonamidszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
CY1106237T1 (el) | Ετepοκυκλικα παραγωγα με 5 μελη στο δακτυλιο και εφαρμογη αυτων ως παρεμποδιστων της μονοαμινο οξυδασης | |
HUP0401982A2 (hu) | Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
ATE135709T1 (de) | Erythromycinderivate, ihr verfahren zur herstellung und ihre verwendung als arzneimitteln | |
HUP0401575A2 (hu) | Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények | |
HU9301645D0 (en) | Method for producing hydroxamic acid derivatives | |
CO4790091A1 (es) | Derivados sustituidos de acido 3-sulfonil-propionico | |
FI956248A (fi) | Uusia välituotteita antihistamiinisten 4-difenyylimetyyli/difenyylimetoksipiperidiinijohdannaisten valmistusta varten | |
HUP0300207A2 (en) | 1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes | |
UA66864C2 (uk) | Похідні сечовини, фармацевтична композиція і спосіб лікування або профілактики запальних, аутоімунних або респіраторних захворювань | |
HUT41713A (en) | Process for production of //arol-cyclobutyl/ alkyl/-amins and medical preparatives containing thereof | |
IL135303A0 (en) | Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents | |
DK0531091T3 (da) | Biologisk nedbrydelig copolyester af 4-hydroxyprolin og farmaceutisk præparat indeholdende samme | |
LV10235A (lv) | Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode | |
HUP0004413A2 (hu) | 2-Aril-3-aroil-benzo[b]tiofének alkalmazása ösztrogén elvonási szindróma kezelésére alkalmas gyógyszerkészítmények előállítására | |
ATE148128T1 (de) | Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung | |
ATE261948T1 (de) | 2-aminothiazol-kondensierte 2-aminoindane und 2- aminotetraline, sowie deren verwendung | |
DE59906041D1 (de) | Glycerylnucleotide, verfahren zu ihrer herstellung und ihre verwendung | |
HUT75647A (en) | Imidazolidinone derivatives and pharmaceutical compositions containing them, which are suitable for treament of senile dementia | |
IL145869A (en) | Process for the production of paclitaxel and nove paclitaxel derivatives | |
UA50722C2 (uk) | Нітробензаміди, спосіб їх одержання (варіанти), фармацевтична композиція | |
HUP0301612A2 (hu) | Új podofillotoxin-karbamát és tiokarbamát vegyületek, eljárás a vegyületek elżállítására, és a vegyületeket tartalmazó gyógyászati készítmények | |
WO2003075928A3 (en) | Stable pharmaceutical compositions | |
ATE261441T1 (de) | Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel | |
ATE234315T1 (de) | Medikamente gegen trhombocytopenie |